The initial management of multiple myeloma in the era of novel agents: 2021 and beyond

Affiliations

¹ Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MD, USA.

Comment

Omar Nadeem et al. Br J Haematol. 2021 Apr.

. 2021 Apr;193(2):213-215.

doi: 10.1111/bjh.17407. Epub 2021 Mar 21.

¹ Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MD, USA.

No abstract available

Comment on

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.
Sive J, Cuthill K, Hunter H, Kazmi M, Pratt G, Smith D; British Society of Haematology. Sive J, et al. Br J Haematol. 2021 Apr;193(2):245-268. doi: 10.1111/bjh.17410. Epub 2021 Mar 21. Br J Haematol. 2021. PMID: 33748957 No abstract available.

1. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22(1):142-54.
1. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727-38.
1. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-21.
1. Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther. 2020;9:201-15.
1. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206-e217.